<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662944</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258A2402</org_study_id>
    <nct_id>NCT04662944</nct_id>
  </id_info>
  <brief_title>A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections</brief_title>
  <acronym>RAZORBILL</acronym>
  <official_title>A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RAZORBILL is an observational, multicenter, multinational, open-label, study designed&#xD;
      primarily to investigate the influence of automated OCT image enrichment with segmentation&#xD;
      information on disease activity assessment in nAMD patients treated with licensed anti-VEGFs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of this study is to assess to what degree disease activity assessment is&#xD;
      influenced and supported by the enrichment of OCT images with segmentation information (i.e.&#xD;
      by identification, highlighting and quantification of pathological fluid compartments&#xD;
      associated with neovascular activity).&#xD;
&#xD;
      The study comprises a prospective data collection phase and a retrospective analysis of OCT&#xD;
      images phase. The prospective observation period per patient will be up to 12 months.&#xD;
&#xD;
      The study will include 720 patients (naïve patients and patients who have been pre-treated&#xD;
      with licensed anti-VEGFs not more than 3 years) being treated for nAMD with brolucizumab,&#xD;
      ranibizumab, or aflibercept according to the respective drug label. Patients will be enrolled&#xD;
      at approximately 20 centers across 6 countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Odds ratio of disease activity identification from Optical Coherence Tomography (OCTs) with and without automatic augmentation</measure>
    <time_frame>12 months</time_frame>
    <description>An odds ratio of disease activity identification from OCTs with and without automatic segmentation will be reported with a 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of agreement in classification of disease activity using segmented OCT images</measure>
    <time_frame>12 months</time_frame>
    <description>Degree of agreement in classification of disease activity assessed by Krippendorff's alpha using segmented OCT images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of agreement in classification of disease activity using non-segmented OCT images</measure>
    <time_frame>12 months</time_frame>
    <description>Degree of agreement in classification of disease activity assessed by Krippendorff's alpha using non-segmented OCT images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess if Discovery is accepted by physicians and whether it can optimize the ophthalmic clinical workflow</measure>
    <time_frame>Month 12</time_frame>
    <description>Physicians will use a digital solution Discovery for managing imaging data and automatic segmentation of OCT volumes. To understand if such a tool is well suited for its role in its current form, holds value for physicians and can optimize clinical workflow, physicians will be invited to complete questionnaires regarding their user experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients absent of Subretinal Fluid, Intraretinal Fluid and Pigment Epithelium Detachment</measure>
    <time_frame>Month 12</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Central Subfield Thickness (CST) change and correlation with Visual Acuity (VA)</measure>
    <time_frame>12 months</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity (VA) change from baseline</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) of patients with ocular and non-ocular adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Detailed Outcome Measure will be defined in the Statistical Analysis Plan</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Licensed anti-VEGFs</arm_group_label>
    <description>Patients being treated for nAMD with licensed anti-VEGFs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brolucizumab</intervention_name>
    <description>There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>Licensed anti-VEGFs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>There is no treatment allocation. Patients administered Ranibizumab by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>Licensed anti-VEGFs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>There is no treatment allocation. Patients administered Aflibercept by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>Licensed anti-VEGFs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects being treated for nAMD with brolucizumab, ranibizumab, or aflibercept according to&#xD;
        the respective drug label.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of nAMD&#xD;
&#xD;
          -  Male and Female patients with ≥40 years of age at index&#xD;
&#xD;
          -  Receipt of at least one injection of brolucizumab, ranibizumab or aflibercept during&#xD;
             the recruitment period&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Patients for whom a therapy with brolucizumab, ranibizumab or aflibercept is medically&#xD;
             indicated according to the respective label&#xD;
&#xD;
          -  Intraretinal and/or subretinal fluid affecting the central subfield of the study eye&#xD;
             at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated for any other retinal disease than nAMD within 6 months prior to the&#xD;
             index date (e.g. patients treated for retinal vein occlusion, diabetic macular oedema,&#xD;
             myopic CNV, and have diagnoses of diabetes-related macular degeneration)&#xD;
&#xD;
          -  Central subfield of the study eye affected by fibrosis or geographic atrophy or total&#xD;
             area of fibrosis &gt;50% of the total lesion in the study eye at screening&#xD;
&#xD;
          -  Any active intraocular or periocular infection or active intraocular inflammation in&#xD;
             either eye at index date&#xD;
&#xD;
          -  Patients who have been on anti-VEGF treatment for longer than 3 years (before index&#xD;
             date)&#xD;
&#xD;
          -  Patients who have any contraindication and are not eligible for treatment with the&#xD;
             chosen anti-VEGF treatment as according to the respective label.&#xD;
&#xD;
          -  Any medical or psychological condition, in the treating physician's opinion, which may&#xD;
             hinder the patient from participating in this study for the expected 12 months&#xD;
&#xD;
          -  Patients participating, in parallel, in an interventional clinical trial&#xD;
&#xD;
          -  Patients participating, in parallel, in any other Novartis sponsored NIS generating&#xD;
             primary data for an anti-VEGF drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>199 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M8X 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>71638</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasnevin</city>
        <state>Dublin 9</state>
        <zip>D09 YN97</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bormujos</city>
        <state>Sevilla</state>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leon</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nAMD</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>RAZORBILL</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>OCT</keyword>
  <keyword>Artificial Intelligence</keyword>
  <keyword>Machine learning</keyword>
  <keyword>Automatic OCT segmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

